- Conditions
- Sarcoma, Soft Tissue
- Interventions
- gemcitabine, vinorelbine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 1,629
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- BMS-813160, Nivolumab, Gemcitabine, Nab-paclitaxel, Biopsy, Peripheral blood
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Malignant Pleural Mesothelioma, Mesothelioma
- Interventions
- Cisplatin, Methotrexate, Gemcitabine, Lung Cancer Symptom Scale for Mesothelioma Questionnaire
- Drug · Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Pancreatic Adenocarcinoma, Metastatic
- Interventions
- Nab-paclitaxel, Gemcitabine, VCN-01
- Drug · Genetic
- Lead sponsor
- Theriva Biologics SL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Newport Beach, California • Sacramento, California • Louisville, Kentucky + 4 more
- Conditions
- Breast Cancer
- Interventions
- gemcitabine hydrochloride, pemetrexed disodium
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 23
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Metastatic Cancer
- Interventions
- BNT141, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Duarte, California • Houston, Texas • San Antonio, Texas
- Conditions
- Myeloma
- Interventions
- Palifermin, Dexamethasone, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant, G-CSF
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Encinitas, California • La Jolla, California + 15 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- gemcitabine hydrochloride, ixabepilone
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- Gemcitabine, Nab-paclitaxel, L-glutamine
- Drug
- Lead sponsor
- Jun Gong, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Los Angeles, California
- Conditions
- Soft Tissue Sarcoma, Bone Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Soft-tissue Sarcoma, Unresectable Bone Sarcoma
- Interventions
- Ascorbate, Gemcitabine
- Drug
- Lead sponsor
- David Dickens
- Other
- Eligibility
- 13 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Lymphoma
- Interventions
- Temsirolimus (CCI-779), Investigator's choice
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Fountain Valley, California • Los Angeles, California + 16 more
- Conditions
- Renal Cell Carcinoma, Neoplasm Metastases
- Interventions
- Gemcitabine, Sunitinib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Neoplasms, Malignant
- Interventions
- cabazitaxel, gemcitabine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
- Conditions
- DLBCL, Diffuse Large B-Cell Lymphoma
- Interventions
- Zilovertamab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Bendamustine, Granulocyte Colony-Stimulating Factor (G-CSF)
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 26
- States / cities
- Glendale, Arizona • Beverly Hills, California • Walnut Creek, California + 23 more
- Conditions
- Cancer
- Interventions
- Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 6 Months to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • St. Petersburg, Florida • Atlanta, Georgia + 1 more
- Conditions
- Advanced Malignant Solid Neoplasm, ALK Positive, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- Ceritinib, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Pancreatic Cancer
- Interventions
- BTH1704, IMPRIME PGG, Gemcitabine
- Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer
- Interventions
- TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel
- Drug
- Lead sponsor
- Tango Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 13 more
- Conditions
- Cancer
- Interventions
- CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab, CGC-11047 and erlotinib, CGC-11047 and cisplatin, CGC-11047 and 5-flurouracil / leucovorin, CGC-11047 and sunitinib
- Drug
- Lead sponsor
- Progen Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 12
- States / cities
- Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 9 more
- Conditions
- Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Interventions
- Pemigatinib, Pembrolizumab, Gemcitabine, Carboplatin
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 13
- States / cities
- Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more
- Conditions
- Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Interventions
- Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 8
- States / cities
- Chandler, Arizona • Tucson, Arizona • Cerritos, California + 4 more
- Conditions
- Mucinous Pancreatic Cysts
- Interventions
- Ethanol, Normal Saline, Chemotherapy
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- capecitabine, gemcitabine hydrochloride, imatinib mesylate, mutation analysis, nucleic acid sequencing, polymerase chain reaction
- Drug · Genetic
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 120 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska